Senesco Technologies Told by FDA It May Proceed Clinical Trials – SNS01-T IND is Open

Senesco Technologies SNT today announced that the Company has been told by the U.S. Food and Drug Administration that all clinical hold issues have been satisfactorily addressed and the FDA has removed the clinical hold on Senesco's Investigational New Drug application. After the Company's supplier provided the requested update to the supplier's Drug Master File and satisfactorily addressed all FDA questions, Senesco was informed by the FDA that it may proceed with its first-in-class clinical study in multiple myeloma. Senesco's IND for SNS01-T is open. “We are very excited to have an open IND which is a significant first for the Company,” stated Leslie J. Browne, Ph.D, President and Chief Executive Officer of Senesco Technologies Inc. “During the delay caused by the DMF, we have progressed towards securing study site approvals and planning the initiation of our SNS01-T clinical study that should start shortly.”